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Patent Laws Of The United States And Canada: Similarities
And Differences
by Roy V Jackson*
INTRODUCTION

Apatent agent in Canada finds that most of the applications to be prepared are filed first in the United States Patent Trademark Office, and
then filed with no substantial change in Canada. Under reciprocity arrangements that favor Canadian agents, they can deal directly with the
Patent Office in Washington, frequently interviewing examiners, and

often the U.S. patent prosecution is completed before the Canadian case
is examined. If it is successful, allowance in Canada usually follows almost automatically.
On the other hand, a Canadian attorney in the United States, working primarily on foreign cases, may prosecute very few U.S. cases, and
spend much time editing U.S. cases for filing in other countries, usually
including Canada, and prosecuting them while keeping in touch with the
U.S. prosecution history. The result is a special perspective from which
to view the differences between the U.S. and Canadian approaches to
patent laws, in a broader international context.
I.

MAJOR SIMILARITIES

1. Background
In both the United States and Canada, power is shared between a

Federal Government and its territorial units - States or Provinces, respectively. In both, the Federal Government administers the patent law.
Also in both, there are two levels of court systems, with overlapping or
exclusive jurisdictions depending on the subject matter and remedies
sought. In the United States, trial jurisdiction over patent matters is in
the Federal District Courts; in Canada there is overlapping jurisdiction,
but the majority of patent cases are tried in the Federal Court. Both
countries owe the basic concepts of their patent systems to the ancient
Statute of Monopolies, passed by the British Parliament in 1623.
2. Current Statutes
The United States Constitution expressly provides for a patent law
* Associated with Hercules, Inc.. Mr. Jackson heads Hercules' international filing and prose-

cution program.

CANADA-UNITED

STATES LAW JOURNAL

Vol. 11:83 1986

in Article I, Section 8: "The Congress shall have power.., to promote
the progress of the useful arts, by securing for limited times to ...inventors the exclusive right to their ...discoveries." The latest basic patent
statute, Title 35 of the U.S. Code (Title 35), dates back to 1952. The
Canadian Patent Act (Patent Act), which also dates back to 1952, has
many of its basic principles modeled upon earlier United States patent
laws, including its definition of an invention: "....

any new and useful

art, process, machine, manufacture or composition of matter.... ."' Despite subsequent divergence due to changes in the U.S. laws, there are
still large areas of major similarity.
3. Some Specific Similarities.
(a) The Term of Patents is the same in both countries - seventeen
years from the date of grant or issue. Unfortunately, there is no maximum limit for the term counted from the filing date, such as is found in
most European domestic patent systems. A maximum limit would avoid
the disruption in industry caused by the issuance of claims that are unreasonably delayed and have been in prosecution for many years: by that
time, the technology covered will become accepted through independent
developments.
(b) Patentable Subject Matter. In this area, both systems have
similar standards of novelty and inventive level. Rejections by the Examiners in both countries are appealable to an Appeal Board. On contemporary and controversial subjects, such as methods including
computerized steps, or involving living matter, the appeal decisions have
conformed generally to the U.S. pattern. However, Canadian case law
has tended to depart from the U.S. interpretation of the terms "art, process, machine, manufacture or composition of matter." For instance,
claims to methods of medical treatment, which in principal have been
approved by the U.S. cases, were disallowed by the Supreme Court of
Canada.2
(c) Presumption of Validity. In both countries, an issued patent is
presumed to be valid, subject to rebuttal by appropriate evidence. The
statutory presumption in Title 35 applies independently to every claim of
a patent.' In Canada the presumption of validity extends to every aspect
of validity: novelty, inventive step, utility, ambiguity, sufficiency, or any
failure to meet a statutory requirement.4
(d) "First-To-Invent" Systems. Both of our systems legally define
a date called the "date of invention," and grant protection only to an
invention that has not been known or used by any person other than the
inventor before that date. In other words, the right to a patent can del
2

Patent Act, R.S.C. ch. P-4, § 2 (1970); 35 U.S.C. § 101 (1982) [hereinafter Patent Act].
Tennessee Eastman v. Commissioner, 1974 S.C.R. 111.

3

35 U.S.C. § 282 (1982).

4

Id. at § 47.
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pend on proof of a complicated legal construction, rather than being
based on the public record of a filing date. The act of an invention is so
subjective that its precise timing is incompatible with abstract legal definition. Experience suggests that the first-to-file system, found in all other
industrialized countries as well as in the European Patent Convention, is
far more in keeping with the needs of contemporary research and
development.
(i) There are minor variations in "first to invent" rules between the two systems, as might be expected in such a conceptual jungle.
As defined in Title 35, "first to invent" essentially means first in the
United States.' In other words, the only public use or knowledge that
counts must be found in the United States. An earlier patent or printed
publication, however, anywhere in the world is a bar, which amounts to
a legal presumption that it is accessible to anyone in the United States,
and raises the much-debated question "What is a printed publication?".
Even a "laid open" foreign application has been held to qualify as a
printed publication.6 In Canada under the Patent Act, it's a little less
complicated; first to invent means first anywhere.
(ii) Both Title 35 and the Patent Act share "statutory bars."
In both systems, even the first inventor can lose the right to the issuance
of patent because of a statutory bar. Statutory bars are created by the use
or sale of the invention within the country in which the patent has been
applied for, or a description published in a patent or printed publication
anywhere that antedates the filing date of an application by a statutory
time period - the "grace period." In the United States, the "grace period" is a year after such use, sale or publication.7 If an application is
filed on the same invention in another country, and the foreign patent
issues before the U.S. filing date, that grace period applies to the foreign
filing date.8 The first inventor also can lose his rights by "abandonment."9 In Canada, the Patent Act allows two years to file, but the twoyear grace period does not apply to an earlier patent that is the foreign
version of the Canadian application for the same invention. 10
(iii) Both countries belong to the Paris Convention. That
means that the priority date of the first filing is preserved for subsequent
foreign filings made up to a year later, but only if the benefit of the International Convention is claimed. Because of the two-year Canadian grace
period, however, Canadian filings corresponding to a first filing elsewhere
(in the U.S. for instance) do not need the one year benefit of the International Convention as a defense against prior publication, use or sale. It
can sometimes be useful, however, because it overcomes the blocking ef35 U.S.C. § 102(b) (1982).
In re Wyer, 655 F.2d 221 (C.C.P.A. 1981).
7 35 U.S.C. § 102(d) (1982).
8 Id. at § 102(c).
9 Id. at § 282.
10 Id. at § 28.
5
6
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fect of any foreign version of the inventor's Canadian application, in the
unlikely event that the foreign patent should issue during the Convention
year. That situation has already been mentioned as the only exception to
the two-year grace period in Section 28 of the Canadian statute. (It can
happen, for instance, if a patent application is filed in Belgium soon after
a Convention first filing in the U.S., and the Belgian patent issues before
filing in Canada).
(iv) Both Canadian and U.S. multinational corporations share
the dangers of reliance on domestic grace periods. If a company with
international interests relies on the grace period for domestic filing after a
publication or sale, it can lose all rights to a patent in an important foreign country. A disclosure before the first filing date is a statutory bar in
all countries that have first-to-file systems, which means most of the
world. So the U.S. and Canadian grace periods often serve as a trap for
over-enthusiastic marketing managers who count on the grace period in
the U.S. or Canada to rush a new product onto the market before filing
an application in their own country.
(e) Priority of Invention. This subject involves the question "Who
is the first inventor when more than one application that claims the same
invention has been filed?" If the conceptual complications of the first-toinvent systems already described aren't enough to make a first-to-fie system look good, the convoluted procedures that the U.S. and Canada have
worked out to answer that question should be more than sufficient.
(i) Interference proceedings are used to determine priority of
invention in the United States. Under the judicial interpretations of 35
U.S.C. § 102 an invention requires two steps: conception and reduction
to practice. The latter may be either actual or constructive and must be
linked to conception by a degree of activity constituting something called
"diligence." The body of administration and law involved in this interference process would probably be sufficient to administer a complete
first-to-file patent system.
(ii) In Canada, conflict proceedings between pending applications correspond to U.S. interferences, but do not involve questions of
priority between a pending application and an issued patent. Under Section 45, the first inventor is the person who can prove that he has formulated, either in writing or orally, a description that "provides the means
for making that which he has invented."" The definition enables the
inventor to establish his date as whenever the description was formulated. A reduction to practice as recognized in the United States is not
an element in the determination of date of invention in Canada. Where
two or more applications for the same invention are filed, the Commissioner of Patents will determine first inventorship on the above basis,
using affidavit evidence only. The losing party in this proceeding can
Il Christiani v. Rice, 1930 S.C.R. 443, 456, aft'd, 1931 A.C. 700 (P.C.).
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then start over in the Federal Court (previously called the Exchequer
Court) if sufficiently displeased with the Commissioner's decision.
(iii) An attack on an issued patent based on priority of invention is treated differently in the two countries. Title 35 U.S.C. treats
interferences between pending applications and issued patents like those
between applications. 2 In Canada, only the Federal Court has jurisdiction to declare a patent invalid. The alleged first inventor is not entitled
to invalidate the patent unless a) the subject matter of the invention was
made available to the public before the filing date of the application for
the issued patent, or b) an application for the patent was ified that should
have been put into conflict proceedings with the application for the is-

sued patent. 13

II.

1.

MAJOR DIFFERENCES:

Background

The Canadian Statute differs more fundamentally from the U.S. system in provisions taken from United Kingdom statutes, and in provisions
unique to Canada. The Canadian court traditions and procedures are
also closer to the British model.
(a) Under certain conditions, the claims of a U.S. application are
entitled to the benefit of the filing date of an earlier-filed U.S. application. 14 There must be continuity of prosecution between the two applications, and the filing date benefit applies only to the subject-matter
disclosed in the earlier U.S. application. If there is new subject matter, it
takes its own filing date. Canada does not enjoy the benefit of continuation or continuation-in-part applications, although the Rules under the
Patent Act introduce another kind of "internal priority." An applicant
filing an amendment to the original application cannot add subject matter that is not included in the disclosure. However, the applicant may file
the subject matter of the amendment in a "Supplementary Disclosure"
(with claims supported by the added disclosure). 15 This "Supplementary
Disclosure" assumes the same filing date as the amendment request.
(b) Products Used for Food or Medicine. Like several other countries, but not the United States, Canada has limitations on patents for
these kinds of products. Section 41(1) of the Canadian Act, prohibits
claims to a substance if it is produced by a chemical process and is intended for food or medicine. The process itself may be patentable and a
product-by-process claim to the substance may be allowed. Fortunately,
the Supreme Court of Canada has held that a process claim is patentable
if the product is novel and has properties that were not obvious, even if it
would have been obvious to produce such a product by the process
12 35 U.S.C. at § 135 (1982).
13 Id. at § 63.
14 Id. at § 120.
15 Rules 53-57, promulgated pursuant to the Patent Act.
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steps.1 6 After several U.S. courts had debated the patentability of a process that depends entirely on the novelty and non-obviousness of the
product, the Court of Appeals of the Federal Circuit held in 1985 that
such a process claim is not allowable. 7
(c) Products Made by a Patented Process. Such products are not
currently covered under Title 35. The U.S. Congress is considering legislation that would make the sale or use of the product of a patented process an infringement of the process patent. However, Canadian
jurisprudence holds that process claims cover the sale or use of the product of the process wherever made. In Canada there is also a rebuttable
presumption that a substance of the same chemical composition and constitution was produced by the same process. In fact, product claims that
depend on process claims are likely to be rejected by the Patent Office for
redundancy.
(d) Compulsory License Provisions. There are no provisions for
compulsory licensing in Title 35. In Canada there are two kinds:
(i) "Abuse" provisions apply to patents that have not been
"worked" in Canada within three years after the grant.18 They are subject to the grant of a compulsory license following proof of circumstances
supporting certain defined "abuses," including failing to work the invention in Canada without sufficient reason, or to supply the demand for the
patented product. These compulsory licensing provisions bring Canada's
law in line with that of most other industrialized nations, other than the
U.S.
(ii) Compulsory licensing of patents relating to food and
medicines are the best-known (one might say most notorious) consequences of the Canadian Patent system. The politically sensitive provisions in Section 41 of the Patent Act probably owe their existence to the
fact that about 95% of Canadian patents are owned or controlled by
foreign corporations, combined with strong public opposition to high
proprietary drug prices, which are seen as a compulsory tribute to foreign companies that have most of their research investment located
outside Canada. However, legislative changes in this area are being
considered.
(e) Jurisprudence. The United States courts rarely refer to decisions in foreign jurisdictions concerning patent matters. On the other
hand, the jurisprudence found in English cases, although not binding, is
usually accepted by Canadian courts as persuasive, despite the fact that
the English decisions are based upon a first-to-file system. Other U.S.
decisions are based upon a first-to-file system. U.S. decisions are frequently cited in argument, but seem to have had little persuasive force
even in areas where the statutory provisions are similar, as already men16
17
18

Ciba v. Commissioner, 1959 S.C.R. 111.
In re Durden, 763 F.2d 1406, (Fed. Cir. 1985), 226 U.S.P.Q. 359.
35 U.S.C. §§ 66-73 (1982).
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tioned in the area of the definition of invention. 19
(f) Maintenance Fees. Maintenance fees were introduced into the
United States statute by amendment in 1982.20 They do not exist in Canada, but they have been a subject of debate since 1960 when a Royal
Commission recommended the introduction of a system of annual renewal fees. 21
(g) Reissue. Both countries provide for the reissue of a defective
or inoperative patent. 22 Only the U.S.A. has an intervening rights provision referring expressly to claims in the reissue patent that differ from
those in the original to protect businesses that would be hurt by such
claims.2 3 Canada has an intervening rights provision that refers to claims
of the original patent,2 4 which originated in a long-lost provision of the
U.S. law. It provides that every person who has "purchased, constructed
or acquired any invention" that is later patented, may without liability
use or sell the "specific article, machine, manufacture or composition of
matter" that constitutes that invention. In some circumstances, this justifies early filing in Canada. This provision may apply to claims in a
Canadian reissue patent that are identical or similar to claims in the reissue patent, but not to claims that differ from those in the original patent,
such as those referred to in 35 U.S.C. § 252.
(h) Marking of a Patented Article. Marking is not required by Title 35, but failure to mark may bar recovery of damages prior to suit for
infringement or other notice.2 5 In Canada, the patent owner is required
to mark the patented article with the word, "Patented," and the year
when the patent issued. The penalty for not marking is a fine of $100.26
There is no other sanction, statutory or otherwise.
(i) Reexamination. There is nothing in the Canadian law that corresponds to the U.S. reexamination proceedings.
(0) Specification and Claims. Claims "particularly pointing out
and distinctly claiming" the subject matter of the invention are required
by Title 35.27 But under the Canadian Act, in addition to the requirement for claims to the novel "things or combinations" that constitute the
invention, 28 the specification is required to "particularly indicate and distinctly claim the part, improvement or combination" which the inventor
claims as his invention. 29 This seems to amount to the same thing as the
19 See text accompanying n.1, supra.
20 35 U.S.C. § 41 (1982).

21 Royal Commission on Patents, Copyright & Industrial Designs, Report on Patents of Invention, 62 (Queen's Printer, Ottawa 1960).
22 35 U.S.C. § 251 (1982); Patent Act, R.S.C. ch. P-4, § 50 (1970).
23 35 U.S.C. § 252 (1982).
24 Id. at § 58.
25 Id. at § 287.
26 Id. at §§ 24 and 77.
27 Id. at § 112.
28 Id. at § 28(2).
29 Id. at § 36(1).

CANADA-UNITED STATES LAW JOURNAL

Vol. 11:83 1986

Jepson Type claim format in U.S. practice, and also to the required form
for European claims, which must have an introduction acknowledging
the closest prior art and a characterizing part defining what is new.
Judging by the form of claims in most U.S. patents on improvement inventions, many U.S. attorneys seem to have ignored the provisions of
Rule 75(e) of the Rules of Practice and the jurisprudence cited in
Anthony W. Deller's Patent Claims, 30 which together provide strong reasons for distinguishing between old and new elements in such inventions.
Their Canadian associates normally see little need to edit corresponding
applications in Canada to meet the specific requirements of Section 36(1),
so long as the specification contains a "statement of the invention" corresponding to the broadest claim.
Editing U.S. cases for filing in other countries is frequently complicated by the failure of the original description to distinguish between old
and new elements. Sometimes it is necessary to review the invention with
the inventor to determine just where in the original description the real
inventive novelty is described, resulting in new insights and changes that
require a new foreign filing license and a refiling of the U.S. case. These
experiences suggest that the European approach can lead to more thoroughly thought-out patent drafting that also conforms to the U.S. Rules
of Practice and the Canadian Patent Act.

30 A. DELLER, 3 PATENT CLAIMS 1-37 (2d ed. 1971).

